Study on the effect of combination therapy of alpha-1 blocker and transdermal oxybutynin hydrochloride in patients with overactive bladder due to benign prostatic hyperplasia

Study on the effect of combination therapy of alpha-1 blocker and transdermal oxybutynin hydrochloride in patients with overactive bladder due to benign prostatic hyperplasia - Study on the combination therapy of alpha-1 blocker and transdermal oxybutynin in patients with overactive bladder due to benign prostatic hyperplasia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021414

Enrollment

Registered

2016-04-01

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with overactive bladder due to benign prostatic hyperplasia

Interventions

Addition of transdermal oxybutynin hydrochloride 73.5mg once per day for 4weeks Monotherapy of alpha-1 blocker

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with LUTS/BPH who have urgency score of OABSS 2 or more, and total score of OABSS 3 or more after taking alpha-1 blocker for 4 weeks or more

Exclusion criteria

Exclusion criteria: Qmax on uroflowmetry 5ml/sec or less, postvoid residual urine 100ml or more, patients who underwent radiation to the prostate

Design outcomes

Primary

Measure	Time frame
Change in total score of overactive bladder symptoms score(OABSS) 4weeks after the intervention	—

Secondary

Measure	Time frame
Change in each item of OABSS 4weeks after the intervention Change in International Prostate Symptoms Score 4weeks after the intervention	—

Countries

Japan

Contacts

Public ContactNaoki Wada

Asahikawa Medical University Department of Renal and Urologic Surgery

nwada@asahikawa-med.ac.jp0166-68-2533

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026